CN102638980A - 噻唑烷二酮能量限制拟似剂 - Google Patents

噻唑烷二酮能量限制拟似剂 Download PDF

Info

Publication number
CN102638980A
CN102638980A CN2010800559152A CN201080055915A CN102638980A CN 102638980 A CN102638980 A CN 102638980A CN 2010800559152 A CN2010800559152 A CN 2010800559152A CN 201080055915 A CN201080055915 A CN 201080055915A CN 102638980 A CN102638980 A CN 102638980A
Authority
CN
China
Prior art keywords
thiazolidine
benzylidene
trifluoromethyl
methyl
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800559152A
Other languages
English (en)
Chinese (zh)
Inventor
C-S.陈
J-H.古
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohio State University Research Foundation
Original Assignee
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio State University Research Foundation filed Critical Ohio State University Research Foundation
Publication of CN102638980A publication Critical patent/CN102638980A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CN2010800559152A 2009-10-09 2010-10-11 噻唑烷二酮能量限制拟似剂 Pending CN102638980A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25004509P 2009-10-09 2009-10-09
US61/250045 2009-10-09
US30488110P 2010-02-16 2010-02-16
US61/304881 2010-02-16
PCT/US2010/052151 WO2011044548A1 (en) 2009-10-09 2010-10-11 Thiazolidinedione energy restriction-mimetic agents

Publications (1)

Publication Number Publication Date
CN102638980A true CN102638980A (zh) 2012-08-15

Family

ID=43855337

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800559152A Pending CN102638980A (zh) 2009-10-09 2010-10-11 噻唑烷二酮能量限制拟似剂

Country Status (6)

Country Link
US (1) US8383656B2 (https=)
EP (1) EP2488027A4 (https=)
JP (2) JP5847085B2 (https=)
CN (1) CN102638980A (https=)
CA (1) CA2777406A1 (https=)
WO (1) WO2011044548A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105315223A (zh) * 2015-11-06 2016-02-10 河南大学 一种高立体和高对映选择性噻唑烷二酮类化合物、其制备方法及应用
CN111675673A (zh) * 2020-06-22 2020-09-18 郑州大学 3，4-二羟基肉桂酸酯类衍生物及其制备方法和应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9056862B2 (en) * 2011-05-10 2015-06-16 National University Corporation Kobe University Thioxothiazolidine derivative having Ras function inhibitory effect
WO2013148994A1 (en) * 2012-03-28 2013-10-03 The Ohio State University Research Foundation Glucose transporter inhibitors
CA2898732A1 (en) * 2013-01-18 2014-07-24 Mao CHENGJIAN Estrogen receptor inhibitors
US12150935B1 (en) 2024-04-16 2024-11-26 Imam Mohammad Ibn Saud Islamic University 3-(3-(1,3-dioxoisoindolin-2-yl) propyl)-5-(4-fluorobenzylidene) thiazolidine-2,4-dione as a potential antitumor and apoptotic inducer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004033438A1 (en) * 2002-10-08 2004-04-22 Theracos, Inc. Novel heterocyclic analogs of diphenylethylene compounds
WO2006069217A2 (en) * 2004-12-22 2006-06-29 The Ohio State Research Foundation Small molecule cyclin d1 ablative agents
CN101014327A (zh) * 2004-07-14 2007-08-08 詹森药业有限公司 用于治疗雌激素相关α受体介导的疾病的亚芳基类物质
WO2009064486A2 (en) * 2007-11-15 2009-05-22 Musc Foundation For Research Development Inhibitors of pim protein kinases, compositions, and methods for treating cancer
WO2009105621A1 (en) * 2008-02-22 2009-08-27 The Ohio State University Research Foundation Androgen receptot-ablative agents

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1003083A (en) 1961-01-21 1965-09-02 Toshiyasu Kasai Novel 4-alkoxynaphthalimides
GB962019A (en) 1961-04-12 1964-06-24 Mitsubishi Chem Ind Naphthalimide optical whitening agents
JPS4957048A (https=) 1972-10-04 1974-06-03
JPS5697277A (en) 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
US4814366A (en) 1986-10-07 1989-03-21 Mitsubishi Chemical Industries Limited Thermoplastic polyester resin composition
JPS6424852A (en) 1987-07-21 1989-01-26 Mitsubishi Chem Ind Polyamide resin composition
EP0335595B1 (en) 1988-03-29 1994-06-08 Mitsubishi Kasei Corporation Thermoplastic polyester resin composition and molded articles produced therefrom
JP2792111B2 (ja) 1989-06-16 1998-08-27 三菱化学株式会社 ポリエステル樹脂成形体の製造方法
ATE205206T1 (de) 1990-04-27 2001-09-15 Sankyo Co Benzylidenthiazolidinderivate, ihre herstellung und ihre anwendung als lipidperoxid-inhibitoren
JP3020353B2 (ja) 1992-07-21 2000-03-15 ポーラ化成工業株式会社 化粧料
US6046222A (en) 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
JPH07247978A (ja) 1994-03-14 1995-09-26 Hitachi Ltd 冷媒ポンプ
EP0682145B1 (en) 1994-05-12 2004-08-25 Ciba SC Holding AG Textile treatment
GB9409466D0 (en) 1994-05-12 1994-06-29 Ciba Geigy Ag Textile treatment
US5801173A (en) 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
JP2817708B2 (ja) 1996-05-29 1998-10-30 日本電気株式会社 有機非線形光学材料及び有機非線形光学素子
JP2003508391A (ja) 1999-08-31 2003-03-04 マキシア・ファーマシューティカルズ・インコーポレイテッド ベンジリデン−チアゾリジンジオン類およびアナログ類ならびに糖尿病の治療におけるその使用
DE10353328A1 (de) 2003-11-14 2005-06-16 Basf Ag Verwendung von Naphthalin-1,8-dicarbonsäuremonoimiden
WO2006069186A2 (en) 2004-12-22 2006-06-29 The Ohio State Research Foundation Small molecule bcl-xl/bcl-2 binding inhibitors
US7608715B2 (en) 2005-11-21 2009-10-27 Sabic Innovative Plastics Ip B.V. Fluorescent brighteners, methods of preparation thereof, fluorescent brightener compositions, and methods of preparation and uses thereof
NZ579372A (en) * 2007-03-07 2012-02-24 Janssen Pharmaceutica Nv Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators
GB0715284D0 (en) * 2007-08-06 2007-09-12 Medical Res Council Crystal structure of ampk and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004033438A1 (en) * 2002-10-08 2004-04-22 Theracos, Inc. Novel heterocyclic analogs of diphenylethylene compounds
CN101014327A (zh) * 2004-07-14 2007-08-08 詹森药业有限公司 用于治疗雌激素相关α受体介导的疾病的亚芳基类物质
WO2006069217A2 (en) * 2004-12-22 2006-06-29 The Ohio State Research Foundation Small molecule cyclin d1 ablative agents
WO2009064486A2 (en) * 2007-11-15 2009-05-22 Musc Foundation For Research Development Inhibitors of pim protein kinases, compositions, and methods for treating cancer
WO2009105621A1 (en) * 2008-02-22 2009-08-27 The Ohio State University Research Foundation Androgen receptot-ablative agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JIAN YANG, ET AL: "Pharmacological Exploitation of the Peroxisome Proliferator-Activated Receptor γ Agonist Ciglitazone To Develop a Novel Class of Androgen Receptor-Ablative Agents", 《J. MED. CHEM.》, vol. 51, no. 7, 13 March 2008 (2008-03-13), pages 2100 - 2107, XP055038068, DOI: doi:10.1021/jm701212m *
JIH-HWA GUH,ET AL: "Development of Novel Adenosine Monophosphate-Activated Protein Kinase Activators", 《 J. MED. CHEM.》, vol. 53, no. 6, 19 February 2010 (2010-02-19), pages 2552 - 2561, XP055038069, DOI: doi:10.1021/jm901773d *
SHUO WEI ET AL: "PPARγ-Independent Antitumor Effects of Thiazolidinediones", 《CANCER LETTER》, vol. 276, no. 2, 18 April 2009 (2009-04-18), XP025995261, DOI: doi:10.1016/j.canlet.2008.08.008 *
SHUO WEI ET AL: "Thiazolidinediones Mimic Glucose Starvation in Facilitating Sp1 Degradation through the Up-Regulation of β-Transducin Repeat-Containing Protein", 《MOLECULAR PHARMACOLOGY》, vol. 76, no. 1, 31 July 2009 (2009-07-31), pages 48 - 2 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105315223A (zh) * 2015-11-06 2016-02-10 河南大学 一种高立体和高对映选择性噻唑烷二酮类化合物、其制备方法及应用
CN111675673A (zh) * 2020-06-22 2020-09-18 郑州大学 3，4-二羟基肉桂酸酯类衍生物及其制备方法和应用
CN111675673B (zh) * 2020-06-22 2022-06-24 郑州大学 3，4-二羟基肉桂酸酯类衍生物及其制备方法和应用

Also Published As

Publication number Publication date
CA2777406A1 (en) 2011-04-14
JP5847085B2 (ja) 2016-01-20
WO2011044548A1 (en) 2011-04-14
US20110086895A1 (en) 2011-04-14
JP2013507397A (ja) 2013-03-04
JP2015098492A (ja) 2015-05-28
EP2488027A4 (en) 2013-04-17
EP2488027A1 (en) 2012-08-22
US8383656B2 (en) 2013-02-26

Similar Documents

Publication Publication Date Title
Flavin et al. Metabolic alterations and targeted therapies in prostate cancer
Yu et al. NVP-BEZ235, a novel dual PI3K–mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells
Kang et al. Lycorine inhibits lipopolysaccharide-induced iNOS and COX-2 up-regulation in RAW264. 7 cells through suppressing P38 and STATs activation and increases the survival rate of mice after LPS challenge
US7060733B2 (en) Methods for treating pancreatitis with curcumin compounds and inhibitors of reactive oxygen species
Ling et al. Novel β-carboline/hydroxamic acid hybrids targeting both histone deacetylase and DNA display high anticancer activity via regulation of the p53 signaling pathway
Ren et al. Discovery of STAT3 and histone deacetylase (HDAC) dual-pathway inhibitors for the treatment of solid cancer
Xu et al. Discovery and modification of in vivo active Nrf2 activators with 1, 2, 4-oxadiazole core: hits identification and structure–activity relationship study
EP2633884A1 (en) Obesity small molecules
JP2015098492A (ja) チアゾリジンジオンエネルギー制限模倣剤
Li et al. Anti-invasive effects of celastrol in hypoxia-induced fibroblast-like synoviocyte through suppressing of HIF-1α/CXCR4 signaling pathway
Hung et al. Bavachinin induces G2/M cell cycle arrest and apoptosis via the ATM/ATR signaling pathway in human small cell lung cancer and shows an antitumor effect in the xenograft model
TW200418460A (en) Methods of using and compositions comprising a JNK inhibitor for the treatment, prevention, management and/or modification of pain
Li et al. Tanshinone IIA suppresses FcεRI-mediated mast cell signaling and anaphylaxis by activation of the Sirt1/LKB1/AMPK pathway
Kimbrough et al. Resveratrol decreases nitric oxide production by hepatocytes during inflammation
BR112019014924A2 (pt) Composição farmacêutica usada para o tratamento de mielopatia associada ao htlv-1
EP3131539B1 (en) Semicarbazide-sensitive amine oxidase inhibitors for use as analgesics in traumatic neuropathy and neurogenic inflammation
JP5792185B2 (ja) 線維増殖性障害および癌からなる群から選択されるβ−カテニン媒介障害を治療するための医薬組成物
Maucort et al. Differentiation of cancer stem cells by using synthetic small molecules: toward new therapeutic strategies against therapy resistance
CN113164446A (zh) 用于抑制和/或治疗代谢病和/或其临床病症的组合物和方法
CA2900413A1 (en) A method of treating obesity
Ahn et al. Scutellarein attenuates cancer cachexia-induced muscle atrophy via targeted inhibition of the JAK/STAT pathway
JP2015504432A (ja) アシル−ヒドラゾンおよびオキサジアゾール化合物、これらを含有する医薬組成物およびその使用
WO2017035529A1 (en) Compositions for app-selective bace inhibition and uses therfor
TWI434680B (zh) 二萜類化合物於治療攝護腺癌之用途
Skogvall et al. Effects of capsazepine on human small airway responsiveness unravel a novel class of bronchorelaxants

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120815